Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

tor-b on early and late activation events
in human T cells. J. Immunol. 150:
3109.
49 Pardoux, C., C. Asselin-Paturel,
J. Chehimi, F. Gay, F. Mami-Chouaib
and S. Chouaib. 1997. Functional interaction
between TGF-b and IL-12 in human
primary allogeneic cytotoxicity and
proliferative response. J. Immunol. 158:
136.
50 Bright, J. J. and S. Sriram. 1998.
TGF-b inhibits IL-12-induced activation
of Jak-STAT pathway in T lymphocytes.
J. Immunol. 161: 1772.
51 Sudarshan, C., J. Galon,Y. Zhou and
J. J. O'Shea. 1999. TGF-b does not inhibit
IL-12- and IL-2-induced activation of
Janus kinases and STATs. J. Immunol.
162: 2974.
52 Weller, M., D. B. Constam, U. Malipiero
and A. Fontana. 1994. Transforming
growth factor-b2 induces apoptosis
of murine T cell clones without
down-regulating bcl-2 mRNA expression.
Eur. J. Immunol. 24: 1293.
53 Andjelic, S., A. Khanna, M. Suthanthiran
and J. Nikolic-Zugic. 1997.
Intracellular Ca 2+ elevation and cyclosporin
A synergistically induce TGF-b1mediated
apoptosis in lymphocytes.
J. Immunol. 158: 2527.
54 Cerwenka, A., H. Kovar, O. Majdic
and W. Holter. 1996. Fas- and activation-induced
apoptosis are reduced in
human T cells preactivated in the presence
of TGF-b1. J. Immunol. 156: 459.
55 Rich, S., N. Van Nood and H. M. Lee.
1996. Role of a5b1 integrin in TGF-b1costimulated
CD8 + T cell growth and
apoptosis. J. Immunol. 157: 2916.
56 Zhang, X., L. Giangreco,
H. E. Broome, C. M. Dargan and
S. L. Swain. 1995. Control of CD4 effector
fate: transforming growth factor b1
and interleukin 2 synergize to prevent
apoptosis and promote effector expansion.
J. Exp. Med. 182: 699.
57 Schiott, A., H. O. Sjogren and
M. Lindvall. 1998. The three isoforms
of transforming growth factor-b co-stimulate
rat T cells and inhibit lymphocyte
apoptosis. Scand. J. Immunol. 48:
371.
References
58 Genestier, L., S. Kasibhatla, T. Brunner
and D. R. Green. 1999. Transforming
growth factor b1 inhibits Fas ligand
expression and subsequent activationinduced
cell death in T cells via downregulation
of c-Myc. J. Exp. Med. 189:
231.
59 Chung, E. J., S. H. Choi,Y. H. Shim,
Y. J. Bang, K. C. Hur and C. W. Kim.
2000. Transforming growth factor-b induces
apoptosis in activated murine T
cells through the activation of caspase
1-like protease. Cel.l Immunol. 204: 46.
60 Sillett, H. K., S. M. Cruickshank,
J. Southgate and L. K. Trejdosiewicz.
2001. Transforming growth factor-b
promotes ªdeath by neglectº in post-activated
human T cells. Immunology 102:
310.
61 Rook, A. H., J. H. Kehrl, L. M. Wakefield,
A. B. Roberts, M. B. Sporn,
D. B. Burlington, H. C. Lane and
A. S. Fauci. 1986. Effects of transforming
growth factor b on the functions of
natural killer cells: depressed cytolytic
activity and blunting of interferon responsiveness.
J. Immunol. 136: 3916.
62 Kuppner, M. C., M. F. Hamou, S. Bodmer,
A. Fontana and N. de Tribolet.
1988. The glioblastoma-derived T-cell
suppressor factor/transforming growth
factor b2 inhibits the generation of lymphokine-activated
killer (LAK) cells. Int.
J. Cancer 42: 562.
63 Brooks, B., K. Chapman, J. Lawry,
A. Meager and R. C. Rees. 1990. Suppression
of lymphokine-activated killer
(LAK) cell induction mediated by interleukin-4
and transforming growth factor-b1:
effect of addition of exogenous
tumour necrosis factor-a and interferon-g
and measurement of their endogenous
production. Clin. Exp. Immunol.
82: 583.
64 Malygin, A. M., S. Meri and T. Timonen.
1993. Regulation of natural killer
cell activity by transforming growth factor-b
and prostaglandin E 2. Scand. J.
Immunol. 37: 71.
65 Fong, L. and E. G. Engleman. 2000.
Dendritic cells in cancer immunotherapy.
Annu. Rev. Immunol. 18: 245.
66 Banchereau, J., F. Briere, C. Caux,
J. Davoust, S. Lebecque,Y. J. Liu,
139